Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity

Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments

Wholesale Weight Loss: Sesame Unveils Specialized Care for Weight Loss with Pricing Exclusively for Costco Members NEW YORK CITY, April 02, 2024 (GLOBE NEWSWIRE) -- Sesame, the company building a radically new healthcare system for uninsured Americans and those with high-deductible plans,  today unveiled an...

NATIONALLY RANKED ROSEN LAW FIRM Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation – ALT NEW YORK, Feb. 19, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Altimmune,...